A validated method for the simultaneous quantification of cannabidiol, Δ9‐tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open‐label trial
- 23 October 2020
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 13 (3) , 614-627
Abstract
Cannabidiol (CBD) and Δ9‐tetrahydrocannabinol (THC) are the two best known and most extensively studied phytocannabinoids within Cannabis sativa. An increasing number of preclinical studies and clinical trials have been conducted with one or both compounds, often probing their therapeutic effects in conditions such as paediatric epilepsy, anxiety disorders or chronic pain. Accurate monitoring of THC and CBD and their metabolites is essential for tracking treatment adherence and pharmacokinetics. However, fully validated methods for the comprehensive analysis of major Phase I CBD metabolites are yet to be developed due to a historical lack of commercially available reference material. In the present study, we developed, optimised and validated a method for the simultaneous quantification of CBD, THC and their major Phase I metabolites 6‐hydroxy‐CBD (6‐OH‐CBD), 7‐hydroxy‐CBD (7‐OH‐CBD), 7‐carboxy‐CBD (7‐COOH‐CBD), 11‐hydroxy‐tetrahydrocannabinol (11‐OH‐THC) and 11‐carboxy‐tetrahydrocannabinol (11‐COOH‐THC) as per Food and Drug Administration (FDA) guidelines for bioanalytical method validation. The method is accurate, reproducible, sensitive and can be carried out in high‐throughput 96‐well formats, ideal for larger scale clinical trials. Deuterated internal standards for each analyte were crucial to account for variable matrix effects between plasma lots. The application of the method to plasma samples, taken from people who had been administered oral CBD as part of an open‐label trial of CBD effects in anxiety disorders, demonstrated its immediate utility in ongoing and upcoming clinical trials. The method will prove useful for future studies involving CBD and/or THC and can likely accommodate the inclusion of additional metabolites as analytical reference materials become commercially available.Keywords
This publication has 29 references indexed in Scilit:
- Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in TherapyCannabis & Cannabinoid Research, 2016
- Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatography‐tandem mass spectrometryDrug Testing and Analysis, 2014
- Tolerance to Effects of High-Dose Oral Δ9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis SmokersJournal of Analytical Toxicology, 2012
- Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomesLife Sciences, 2011
- Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometryAnalytical and Bioanalytical Chemistry, 2011
- Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ9-Tetrahydrocannabinol and Oromucosal Cannabis Extract AdministrationClinical Chemistry, 2011
- Human Cannabinoid PharmacokineticsChemistry & Biodiversity, 2007
- Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extractsJournal of Chromatography B, 2007
- Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomesLife Sciences, 2007
- Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MSAnalytical Chemistry, 2003